Mei-Jung Lai — 臺北醫學大學

查看斯高帕斯 (Scopus) 概要

h-index

每年研究成果

如果您對這些純文本內容做了任何改變，很快就會看到。

學歷

2010 臺北醫學大學藥學系博士
2006 University of Sourhern CaliforniaPharmaceutical Sciences 碩士
2001 臺北醫學大學藥學系學士

經歷

2019.12- 臺北醫學大學生技醫療產業研發博士學程副研究員
2019.02- 臺北醫學大學生技醫藥商品化中心副研究員
2018.04-2019.01 臺北醫學大學生技醫藥商品化中心助理研究員
2016.11-2018.03 臺北醫學大學癌症轉譯研究中心助理研究員
2014.08-2016.10 臺北醫學大學轉譯醫學研究中心助理研究員
2013.01-2014.07 臺北醫學大學博士後研究員
2012.03-2012.10 食品藥物管理局審查員
2010.08-2012.02 臺北醫學大學博士後研究員

研究興趣

有機合成

指紋

查看啟用 Mei-Jung Lai 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。

1 類似的個人檔案

5 已完成

合成可雙重抑制組織蛋白去乙醯酶6與熱休克蛋白90，並同時調節PD-L1之雜環類抗癌化合物
Lai, M.
8/1/20 → 7/1/21
研究計畫: A - 政府部門 › b - 科技部
組蛋白去乙醯酶在血管認知功能損傷中的作用-組蛋白去乙醯酶調節者在血管認知損傷動物可作為新的治療
Lai, M.
1/1/19 → 12/1/19
研究計畫: A - 政府部門 › d - 教育部
設計與合成聯芳基及二苯胺基取代之磺胺類抗癌化合物
Lai, M.
8/1/16 → 7/31/17
研究計畫: A - 政府部門 › b - 科技部
TMU103-AE1-B09
Lai, M.
11/1/14 → 10/31/16
研究計畫: B - 校內計畫 › g - 新聘教師研究補助
設計與合成新穎苯甲醯胺與醯基羥胺取代之雜環化合物分別抑制微小管與組織蛋白去乙醯酉每6為抗癌藥物
Lai, M.
11/1/14 → 10/31/15
研究計畫: A - 政府部門 › b - 科技部

42 文章
3 評論/辯論

CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition
Singh, A., Chang, T. Y., Kaur, N., Hsu, K. C., Yen, Y., Lin, T. E., Lai, M. J., Lee, S. B. & Liou, J. P., 4月 5 2021, 於: European Journal of Medicinal Chemistry. 215, 113169.
研究成果: 雜誌貢獻 › 文章 › 同行評審
9 引文斯高帕斯（Scopus）
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Mehndiratta, S., Chen, M. C., Chao, Y. H., Lee, C. H., Liou, J. P., Lai, M. J. & Lee, H. Y., 12月 2021, 於: Journal of Enzyme Inhibition and Medicinal Chemistry. 36, 1, p. 74-84 11 p.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma
Nepali, K., Hsu, T. I., Hsieh, C. M., Lo, W. L., Lai, M. J., Hsu, K. C., Lin, T. E., Chuang, J. Y. & Liou, J. P., 5月 5 2021, 於: European Journal of Medicinal Chemistry. 217, 113338.
研究成果: 雜誌貢獻 › 文章 › 同行評審
4 引文斯高帕斯（Scopus）
Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo
Liu, Y. M., Tu, H. J., Wu, C. H., Lai, M. J., Yu, S. C., Chao, M. W., Wu, Y. W., Teng, C. M., Pan, S. L. & Liou, J. P., 7月 5 2021, 於: European Journal of Medicinal Chemistry. 219, 113428.
研究成果: 雜誌貢獻 › 文章 › 同行評審
4 引文斯高帕斯（Scopus）
The HDAC/HSP90 inhibitor G570 attenuated blue light-induced cell migration in RPE cells and neovascularization in mice through decreased VEGF production
Hsu, T. J., Nepali, K., Tsai, C. H., Imtiyaz, Z., Lin, F. L., Hsiao, G., Lai, M. J. & Cheng, Y. W., 7月 2 2021, 於: Molecules. 26, 14, 4359.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 5月 29 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
資料集: Dataset
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 5月 29 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://doi.org/10.6084%2Fm9.figshare.c.4522856.v1
資料集: Dataset
Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 5月 29 2019
DOI: 10.6084/m9.figshare.8202881.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202881/1
資料集: Dataset
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 5月 29 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://springernature.figshare.com/articles/Additional_file_5_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202902/1
資料集: Dataset
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Contributor), Liou, J. (Contributor), Teng, C. (Contributor) & Pan, S. (Contributor), Unknown Publisher, 5月 29 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
資料集: Dataset